Q1 2020 Earnings Call

[music].

Ladies and gentlemen, this is the operator today's conference is scheduled to begin momentarily until that time your lines will again be placed on music hold thank you for your patience.

[music].

Ladies and gentlemen, thank you for standing by and welcome to the Elephant vital science is Q1, what do you foresee financial results call.

This time, all participants are in a listen only mode.

After the speaker presentation, there will be a question and answer session.

Asked a question during the session you will need to press star one on your telephone.

Please be advised that today's conference is being recorded.

If you require any further assistance please press star zero.

I'll now turn the call overseas, Amy Raskopf ever from vital science its head of Investor Relations. Please go ahead.

Thank you and good morning, everyone. If you haven't done they've already I encourage you to access the Q1 2020 presentation and the press release issued earlier today, both of which are at Apple found dotcom under the investors tab before we begin I would like to remind you that my remarks on this call will contain forward looking statements, but you made only as of today may six.

2020.

For a more detailed description of important risk factors that could cause our actual results to differ materially. Please refer to our annual report on form 10-K and are most recently filed 10-Q with that I'll turn the call over just dunker pellet here I've often CEO.

Thank you Amy Hello, everyone and thank you for joining us this morning.

In the middle of this environment and the daily influx of Cobot 19 update I'm actually credits, we see share either this call will be field predominantly with good news, though.

This is a great quarter for US we've had tremendous mine and we expect the month ahead to be transform.

With that said [laughter] call I'd like to lease wrapping unexpected passing of our chairman Han watch in early April.

He was a very clever strategists. He was a staunch advocates for Britain and he was a true friends.

And to me personally.

This will certainly be now and I am, particularly sad that he will not be here to see a spring sexy over the approval finish line, but your honoring is memory by focusing all of our energy on nickel.

One of our current board members Dr. William Hall Graciously accepted for examination to serve interim chairman Dr. Halderman down expert [laughter] diseases and Barovsky served on our board public in January 2018, and we appreciate all going leadership and willingness to take on additional though.

So turning now to happier topic, we are less than three weeks away from the FDA PDUFA date, perfecting our innovative hormone free woman control on demand contraceptive, Canada [laughter] as expected we are right in the middle legal discussions with the I guess.

Well it doesn't guarantee approval, we are highly encouraged by our interaction and we look forward to the east decision on or before May 20 that did you today.

Second you recently secured up to 25 billion dollar nature I fight.

No.

[laughter], it often very difficult to secure and difficult to close during the back to time, but in the current who'll be 19 environment with incredible volatility the financial market uncertainty all around.

Leave this show support from our Investor, particularly ahead of the anticipated approval affect the speaks volumes about their competent than ever with them and their belief in the school market potential effects.

And third we have created a comprehensive wash plant that Rob will speak to it.

It addresses the current gaps in women's contraceptive health needs, while ensuring the ease of access for women through a robust tele contraceptive platform with related services.

The plan is designed to maximize the potential effects, the and drive what we believe could be one of the most successful launches in wind itself.

Turning to our pipeline. The team is looking forward to or end of phase two discussion with the FDA later today to review the result of the temperaments trial and to discuss the potential clinical and regulatory path forward for even a 100, which is our investigational MPPR candidate for the prevention of Chlamydia and gonorrhea infinite.

Sure, we announced positive top line data from this landmark phase Twob study in December which shows that no 100 met both the primary and secondary endpoints of the reduction of chlamydia and gonorrhea and women.

And with more than 1.8 million cases up chlamydia and 600000 cases of gonorrhea reported to the CDC last year, it's yet again, an incredible unmet need for women.

We look forward to gain after your perspective on our plan to prevent increasingly common sexually transmitted infections and the potential to initiate a phase three trial, even 100 by the end of this year.

I could go on and on about all the exciting things happening here it up with them, but I'm going to stop I'm going to turn it over to rest Barron's, our chief commercial officer and he is the gentleman, who is bringing sexy back in the form of sexy.

Now you know Justin Timberlake, he may still habit, but rough is the true key sexy so rough over to you.

Well, you certainly couldn't ask for better reduction, but that thank you Sandra.

Although we do remain in remote work number you can see that song to remain doesn't superyachts because ever and the energy from the full double from team is just as infectious as we head into the potential approval and launch Opex.

It's sort of mentioned we are in label discussions with the FDA. Our sales leadership team has been completed defects University training program and their responsibilities expanded as we move into the launch praised for taxi.

Further we built out and extensive vecsey pellet contraception networks that we believe wall Street access to and uptick Oh Teksid. She did you start with an update on our launch timing and the sales force buildup.

After careful consideration of the impact of Cobot 19 on all aspects of the health care landscape, particularly the restrictions on physician or actions. We've made a strategic decision to push the commercial launch effects due to the first week of September.

All the goal is to ensure that we appropriately anticipate are prepared to address all golden aspects of the current medical office environment.

Most of our planning remains intact, what changes is where we allocate our resources. We can expect evel for him to put more fuel in the tank. If you will for efforts with greater potential impact in this new environment of limited interactions between patients with health care providers and between our sales team and these providers.

So with that in mine, we're reducing the number of sales reps, we plan to hire in preparation for our early September commercial watch previously we anticipated having 125 sales consultants that would cover most of the high prescribers in this category.

We've determined that the right approach is the mix and internal sales team often referred to as Hello detail him with a reduced sales force of two thirds of half of the originally planned size. Our analysis shows we will not give up the number of HCP as we can reach but just not in the old model of rough deployment.

We will keep an eye on the changes taking place at this time in health care promotion and May expand the salesforce over the next 12 to 18 months if appropriate.

We believe this strategic move Leverages, our resources for maximum potential.

Really what that wraparound services elements, we plan to provide that I'm really excited to share a little bit more with you.

So as you know.

We're social doesn't see on restrictions on non essential in person health care appointments Tele medicine has become the norm overnight for conducting annual well visits preexisting conditions, filling prescriptions and and even diagnosing illnesses or injuries or in our case the contraception that's needed by women.

Research insights recently cited contraception is one of the fastest growing therapeutic areas and the Kobin 19 environment for Tele health.

And we believe that she is ideally suited for this virtual and telemedicine platform. It's easy to understand it's easy to use has a very favorable safety profile, which equates to low risk for patients and prescribers.

Now, let me give you a little teaser regarding some new information about the Teksid helicopter subsea network that has been in development by the way since well before the current social distancing and business shutdown and it will be instrumental in the trajectory of our early launch curve and to establishing a whole family as a leader in women's health.

Unlike other pharma companies.

But now they're trying to retrofit how's that they built from the old sales and marketing model, we have the luxury a building our business model in the new reality that will be with us for months and possibly years to come.

So here's how it's going to work.

Working through a country or service for patients a woman won't be able to connect through the effect see consumer website or online banners or even ones existing telemedicine platforms and gain access to appropriate counseling by registered nurse or other health care provider, who can after her question hopper with insurance coverage or what's the Pepsi co pay card and connected to a pharmacy.

That will deliver frutchey right to her door or she prefers she could have a prescription available at our local neighborhood pharmacy.

Part of this platform is our get your sexy on counseling portal, which in addition to teaching women through some really super cool videos about Dixie experience, but also reminds them, but they may be do for her sexy prescription refills.

There are many more exciting things I want to share over the coming months, but I'm going to I mean after kind of move on because I'm getting the I'd from today.

So I could almost here your thoughts.

Yes.

We're pretty confident aren't you.

Well, yes, frankly, I am because my confidence is built on extensive market research among more than 8000 women 2000, it'll be do I have been allied health care professionals and payers, who cover a majority of commercial lives. It's become increasingly clear if you're paying attention that the use of hormones has fallen into just favorite with large numbers of women.

Especially either because of the side effects from birth control. We're just this general desire to avoid all [laughter] body, including food or make up drugs you name it.

Take for example, women's increasing interest in exercise healthy living yoga meditation. These arent direct conflict with their current options for birth control, which are primarily hormonal.

To better quantify the number of women. This segment, we commissioned the KJ T. group to conduct several rounds of consumer research.

The KJ T. consumer segmentation market research, which was conducted among more than 3000 women ages 18 to 44 rebuild some very interesting interest in Texas the across six specific segments, a women and the date are really rich so here's what we thought.

First of all there's about 67 million women of reproductive age 47 million winter <unk> million of them are at risk for becoming pregnant. Among those 47 million women about 19 million or using a prescription contraception, which leaves roughly 28 million women, who are not using a prescription method of contraception, that's that's like 60%.

Let me reiterate 60% of women are at risk for pregnancy, and not using a prescription contraception. That's that's mind boggling at times and all those 20 million women approximately 17 million have already self identified as being beyond hormones. These women are early vecsey women.

From this research we know what these women are currently doing for contraception. Their overall demographics, there marital status the frequency of sex and importantly, there sensitivity to social media and advertising and the channels, we need to use to reach deep segment varies in size from bought a million two three or 4 million in an aggregate comprise.

Why is the 17 million, we've identified as our primary targets for Pepsi.

As a reminder, we also conducted extensive market research among nearly 2000 health care providers with our target product profile and wall appeal is still typically how women entered the contraceptive journey eight cps recognize they lack something off of these women who are beyond hormones and the second product they chose most.

After the pill was the profile, which was for backseat. This gives us great confidence that there is a solid place in the armamentarium of contraceptive products, where we believe that she will be a lead player for a segment of women who up to this point have been left one thing.

Finally, but equally important is our payer research my team recently commissioned the pricing study with Putnam one of the leading health care pricing strategy firms to help us understand the optimal pricing range that would maximize the value of our innovative new non hormonal contraception option without jeopardizing any uptake or coverage by payers.

The Putnam research was conducted among 15 payers that represented about 52% of the commercial lives United States.

And continue to validate our assumptions that first quarter, such as not highly managed in this category consensus among payers is that as long as the cost effects. He is relatively equal to the annual cost of a branded monthly contraception. They expect to cover Betsy. The the research also supports earlier findings that payers expect becsey.

To be widely reimbursed that zero co pay as a covered benefit under the affordable care Act or you see a.

Next well pairs. The fact that with a box of 12 50 applicators women will rebuild their for their effect you prescription on average of six or seven times a year.

With that in mind.

We're looking out of whack price of a range between 250 and $275 robotic 12, which when you do the math the cost for the pair for seven prescription refills affects you will be about the same as a monthly method of contraception on an annualized basis.

Our market access team is already appropriately engaging with payers educating them about half of them and taxi working cross functionally with our 13 regional business managers to provide pre approval information exchange is 125 regional payers.

As a result of these efforts, we expect that 50% to 60% of all payers will have reviewed vecsey by the time, we initiated the commercial launch in early September.

Should we receive approval on or before May 25th we do plan to host a post approval teleconference call during which we will provide more details our commercial campaign, including things I'm really excited about respect to the social and digital media Rollouts. So in summary. This research tells us that we are well.

Employees to the launch of what I believe will be a game changer in this category and with that now I'm going to turn it over to our CFO Jay to discuss our financials for this quarter.

Express for three months ended March 31st 2020, total operating expenses increased 41% to 19.2 million.

The increase was almost entirely associated with our pre commercialization efforts to ensure more prepared for the potential us launch affects the for hormone free women controlled on demand contraception.

Research and development cost decreased 3.7 million or 47% to 4.2 mine.

Clinical trial expenses were 5.1 million lower compared to the prior year quarter due to the timing of completing the clinical phase is both the mpower and improvements trials.

This reduction was offset impart by higher cost for outside services and the current period associated with that actually India. We submission in manufacturing activities in preparation for the anticipated commercial launch as well as higher payroll related expenses and noncash stock based compensation.

Selling and marketing costs were 7.9 million in the first quarter and as I mentioned in our yearend call. This is our first reporting period breaking up. This line item. Therefore, 1.1 billion was reclassified from general and administrative expenses, just selling and marketing for the first quarter of 29 team in order to conform with this new presentation.

The 6.8 million increase over the prior year quarter includes a 3.7 million increase in pre commercialization marketing related expenses, reflecting the preparations for the potential launch FXC for the prevention or pregnancy, and 1.6 million increase in marketing and Med affairs consulting services as well as higher payroll related expenses.

And noncash stock based compensation.

General and administrative costs increased 2.5 million or 54% to 7.1 million in the first quarter of 2020.

The increase reflects higher noncash compensation payroll related expenses and consulting services predominantly related to Salesforce critic.

Net loss was 19.1 million or a loss of 40 cents per share for the first quarter of 2020 compared to a net loss of 18.1 million or loss of 67 cents per share for the prior year quarter.

We closed the quarter with 10.3 million, an unrestricted cash and equivalents and short term investments as compared to 23.8 million at December 30, Onest two to 2019.

To ensure maximum flexibility for lunch launch execution, we are proactively implemented steps to control and consistently review our near term cash burn.

With a strategic decision to move the sexy commercial launch to early September and the related positive self worse hiring until the third quarter, we're forecasting a cash burn of around 13 to 15 million in the second quarter.

As stronger mentioned after a rigorous process conducted during a very challenging time in the financial markets. We raised up to 25 million through a private placement of convertible notes and warrants with healthcare focused institutional investor.

This transaction speaks to their belief and have a fan and the full market potential effects.

$50 million was funded a close and the investor has the option to find an additional 10 million in the future.

This interim financing significantly improves on working capital and our anticipated PDUFA date, and gives us greater flexibility and balance sheet strength in advance of our next round of financing as we ramp up both our pre launch and commercialization activities for taxi.

Finally, as most of you are aware, our former strategic Investor PDL Bio Sciences is in the process of liquidating its assets with the aim of distributing net proceeds solders.

PDL announced yesterday that its board of directors has approved the distribution of is 13.3 million shares of LCM common stock to PDL stockholder through a onetime dividend, which is expected to close on may 21st.

We're pleased with this plan, which differs diversifies what was a highly concentrated position into a much broader shareholder base and we look forward to welcoming and engaging with our new stockholders Annapolis I'm sorry.

And with that I'll turn it back to Sandra.

Thank you Jay so in closing I, just had a few remarks about sexy and the opportunity ahead.

This is our time.

At both then is made up of realist, yes of course, we like optimism like the next person, but we recognize that words are cheap indeed, our dear.

The beauty of this moment in time is that as you heard and rest as analogy. We don't have to pivot we don't have to change the rooms in our house. We're doing this fresh brand new we can build our own footprint based on the market dynamics that exist today and contraception is an incredibly unique category that response to social.

Yeah and to Tele health in a very different way. So we continue to be excited about our approach. What you also know is that we know when something is unique and different and never been done before there are people that they have a hard time embracing it we feel differently based on all the market research that we've done we know.

On the payer research our uniqueness allows us to have strengthened our category. So that really impacts the price we can use and the discounts that we don't have to give and as you heard from Russia millions of women are beyond hormones, primarily due to the very serious side effects that when they may experience with her.

Excellent.

Staying at home has made people focus on their health in different ways, particularly women and we're excited about that and there are millions of other women that are simply over their current options. I. You. These are complicated the condom negotiation can be frustrating and sadly in many cases, a losing proposition permanent and the.

Other current option simply don't speak to their needs.

It's time for something it's time for something women can use at their discretion without the need for daily reminders or hormones. It's time for something that doesn't require women to give up freedom control or power.

Well that is focused on bringing real innovation too. Many I believe is going to the true sexual and reproductive health Revolution, yes that Randy a revolution. The data we shared with you today tell us that millions of other when they feel the exact same way.

So with that I'd like to turn it back to the operator and open the call for questions.

As a reminder to ask a question you will need to press star one on your telephone <unk>.

Withdraw your question press the pound key please standby while be compiled the Q1 day roster.

Your first question comes from Louise Chen with Cantor.

Hi, Thanks for taking my questions here. So I had a few my first question is how are the label discussions progressing relative to your expectations. I know you can't give details, but just curious what you're thinking here and then what does the ideal label look like for you and then in terms of the S.T.I. indication the is already data out.

So effects. He is approved do you anticipate any off label usage.

And then in terms of the launch for September that Youve put off what are you gonna be doing between me and September to prepare for that launch. Thank you.

Kelly <unk>, yes, I'll I'll start testers Kelley Hall, Chief Medical Officer. So the label discussions have been going very well they I'm sorry, exactly on time, and we expected you know just a month or prior to our PDUFA date everything is progressing extremely well, we would in responding either before or at the dead.

Line that the FDA has requested with each set of questions and discussions and so thats progressing you know very well and we feel that we're set to have a very favorable label with regards to what the ideal label would be you know it. It's really just an accurate description of that sees a efficacy in x.

Excellent safety profile, we have discussed the desire to have some of our sexual satisfaction data in the label. We that that is an exploratory endpoint, but we have some very strong arguments for you know eventually getting out and labor. If we don't with this first pass, but you know I think that all they really looking for is just an accurate.

At assessment of that efficacy and safety profile, which is positive and speaks for itself.

And then finally around the.

Oh Jeez I Sci off label use you know we can't speak off label use a we do have a publication in manuscript in process right now that will be published we also have a couple of abstracts and we have submitted for presentation at fall conferences. So this information will be out there but.

Of course me, we wouldn't be able to speak to you off label use and then rest could you addressed and loses question regarding what we're doing between now and September.

Yeah, and so one of the main things will be able to do is once we have up to do for approval and Texas listed in the Compendiums our market access team will be able to start calling on payers as most are aware they have six months to review.

A new drug M., so that clock starts upon PDUFA not upon commercial launch so we will spend time with them, making that happen and in our most recent analysis of other products that have had a a launch some worse in the same neighborhood of three months post the PDUFA they've seen about 50.

60 of those payers a percent of those payers already reviewed the product as well.

Other things will be doing is will be higher in a sales force over the over the summer months, we'll be putting together the final touches around the sexy Tele contraception network will be working together with existing the online Tele medicine groups that are featured for women's health care, specifically and well be making sure that the street.

All in our our channel for distribution has been building is ready to go. So it really will be of excitement very busy time throughout the summer months as we head into September.

Thank you.

Your next question comes from a line of ROM overarching H.C. Wainwright.

Thanks very much for taking my question just a couple of here from me I was wondering if you could just quickly recap again the pricing determinations that you've made so far with respect to sexy and also if you could comment on how you expect pricing for the pro.

Got it could potentially evolve if at all.

One you might potentially get for example, the S.T.I. prevention data onto the label I also wanted to ask whether you think that there is likely to be any potential disadvantage to launching only in September simply because that happens to be the same timeframe from what I under.

Then that core lives gonna be hitting the market. Thank you.

So let me address those are those questions in the first the first on the first part you know what the Putnam research we did.

Was really prompted by we were able to hire a veteran in this space of market access who is.

The last 20 years of his career based on women's health care and comes with a great deal of experience in one of the things that it first struck him why is that when we say where.

We're able to charge the same price as a monthly method of contraception that we were kind of looking at it from a perspective, I'm, saying well a monthly doses of monthly dose, but ours is not monthly so when the research was diamond they started talking to payers what they really understood was that what they are most interested in is when you aggregate that over the course of a.

A year, how do we come out in terms of what it cost them for each woman who's on becsey versus what it cost them to be on another branded monthly contraception. So that's where we came to the place of the range that we provided today and we will be putting into place as we've already instituted a pricing committee as as part of the compliance necessary to do that and that pricing Committee will.

Put into play over the coming.

Weeks, what the final price will be so that it can be listed in the compendium at that time and so then what are the things that we do believe I think it's really important when you talked about you know that the launch of another hormonal method of contraception at the same time is that is that we are not.

Competing with hormones, we are talking about a group of women, who have already declared that they are beyond hormones. So in that regard we're not really at all concerned about the fact in fact, what it will do is a heightened the level of volume around the question of what is an appropriate method of contraception for women and it will give us an opportunity to really placed ourselves in position to say.

For those women who have already.

Stated that there'll be odd hormones or are starting to transition because of the fear of the side effects or the experience of the side effects. It will put us into a great place. So from our perspective, you know that actually just adds to the overall attention to a neglected category over the last couple of decades.

Okay, that's great.

And I'm, just if I could add to that look one of the things that we feel really good about is to rest is point that.

The a woman who is going to be used a patch is predominantly not the same woman who is going to be using sexy and vice versa, and so you know we actually feel like launching at the same time.

Women want choices, we're all about choices and you know, we actually feel really really confident that the women who have said that they are beyond hormone. They are left wanting there is no question that they are left wanting because half of those women say, they're not going to use an eye you de which is the only other prescription choice they have a caprese. So we.

I actually think that regardless of the timing of other products coming to the market that the sexy woman is unique and discrete and we'll be she'll be very very excited to have an auction because now she doesn't happen.

Okay. So I mean, basically you you don't see any real interference from any other promotional activities in the contraceptive space you know regardless of the timing of sexy launch in September in a nutshell right.

That's correct, that's correct and honestly, we really do think you know like this is a candle isn't nothing by letting another candle, meaning we think excitement in the category. We think excitement about women's health. We think you know all of these efforts to really focus on women as the health care consumer, giving these women choices that fit their low.

Right is the right thing and we believe that where the right choice for women, who are beyond hormone, but we have never ever said that we are delusional right. In my talk I said, we're a realist here, we aren't going out targeting women, who can and will use the hormone we're not because that's not our audience. So that's why we feel good that regardless of when we.

On the market that <unk>, the timing is going to be perfect for sexy.

Great. Thank you very much.

Your next question comes from a line of Randall Stanicky with RBC capital markets.

Hi, Good morning, especially are you on Randall.

As you know it sounds like spirits are very high heading into the do fine just great can you talk little bit more about your expectations around initial launch ramp and I know you touched on prior calls, but just wanted to know if your expectations have changed at all or if it's essentially I'm kind of a similar curve as to what you had expected to for it but just push outs to yeah.

Starting in September.

You know just wanting to know a little bit more about the bigger swing factors to us for instance, what are your expectations Brown unemployment at that time, how does that factor in and.

Just the puts and takes obviously your updated pricing is much higher higher range that we had heard before so are you how does that all shake out and are your accordingly, expecting a personal higher peak sales given the higher price range.

Great. Thank you for the question, yes, our spirits are high and you know one of the reasons, where I'll grant pants today, which is very positive and quite encouraged [laughter] [laughter] paradigm that though too much information I'm gonna have rest really address your question initially.

For those who hundred that's just a reference affected founder is not an or pajamas [laughter]. So [laughter]. So [laughter]. So in terms of the launch curve one of the things that we have looked out and again, we were looking at a pretty pretty closely before was what does the promotional spend that you have what what is the history.

Or expand the bad for other brands across that and how what was your share of voice among some of the.

Healthcare providers and what was the level of awareness among consumers. So all those things really factor into that question of what is your curve look like and we have not yet really brought a any guidance to what it would be but as you can see when we talk about our level of of our whack price being at a higher level than we.

Had a anticipated previously we do know that should have an equal effect in terms of of the elasticity around that one of the questions that does come up and I think maybe that's where you're alluding to is how does that affect the level of access because we've been able to determine that under asea will still likely be one of those choices and also.

Even if were put into a higher level of of co pay initially.

But the co pay card, we've got plenty of room in that pricing to give us a place where we still have a a really nice healthy gross to net even at the launch phase. So we don't anticipate that there would be hardly any women who would be denied access because they would have to pay for it completely out of pocket and we anticipate the by the time that we get to launch with the 50% to 60%.

That have already reviewed it that that uptake curve would actually equal or even be better than what we had anticipated when we were thinking about launching immediately after the PDUFA date.

Got it thank you.

Your next question comes from a line of Leland Gershell with Oppenheimer.

Good morning, Thanks for taking my questions.

I want to ask about PTC plans I think in the last call. You had mentioned that you do gearing up for kind of an expedited approval to to launch a DTC and component with the delay and deferral of the lunch time to September could we expect then you having approval.

We're DTC you can see together with them.

Your your you know marketing to physicians and also have a question kind of lead to loosens earlier about not so much off label promotion, but promotion affect c., but being able to provide the data and in the U.S.J. prevention and what you are.

Flexibilities limitation.

It would be to all these provide the data published.

Total as part of your thanks for your most of them. Thanks.

[noise] so.

Good to talk to you Leland and let me just give you the the topline relative to where we're going to be out with DTC. So as we're developing out our sexy telecom perception platform when we come out.

With our commercial launch we will immediately go into a pretty active digital space in terms of getting women.

Aware of the of the brand through online banners and search engine optimization and and all those types of things that really promote women to come into that space, we will be spending time as the as the MSL team is currently now talking to the.

Okay wells, our external experts to make them aware and so we anticipate that you know there will be an awareness of affects the before it comes out now typically brands have to put themselves in a position where they do coming soon campaigns or as we often referred to as Nonbranded before you get approved we're gonna three months after approval that we're going to be able.

Good to talk about what's going on with.

Sexy and what it what will you be available with that coming soon so we anticipate that right out of the gate, we're going to be able to use.

Some some of the.

What is referred to as DTC to really promotes two women, we will still hold to the.

Putting out the online and television commercials and and that broader message to the end of January as we prepare for the the month of February and next quarter or the first quarter of.

21, but we will immediately go out with advertising to those consumers will be engaging with some influencers and social media and some of those kinds of things. So we anticipate that women will begin to here quickly and begin to spread the word quickly and one of the things we'll talk about it in the coming up.

Call is just our our factory posse and what they are those going to be goes ambassadors are going to start talking about their experience.

And can I want to attention.

Yeah.

Yeah, So I'll touch on me on the Sci indication so as Wes mentioned, we already have our medical science liaisons out in the field and they've been out for for several months. They are experts in women's health there nurse practitioners and they have been contacting you know that keeping you meters and health care providers on to talk.

Then about you know our data so as we get our you know publications and if you read the journals and also the presentations in the fall conferences, which will you know a line nicely with our launch plans up you did they will continue to be able to talk to health care providers about this data you know in health care providers are these there are pretty sophisticated when it comes to understanding.

And you know the relevance of this data, especially for their patient populations. So you know while we obviously, it's not going to be in label Im not going to be able to permit it from a two marketing perspective, we do have that sort of scientific exchange opportunity both through conferences publications and our medical science liaisons.

Thanks, very much in it keeps retention.

[laughter], Oh, yeah, well there [laughter].

I will now turn the call back to Sondra pellets here for any closing remarks.

Well. Thank you so much operator, and I want to thank everybody for joining us. This morning, we really appreciate the ongoing interest and the ongoing supportive ever fan and we look forward to speaking with you soon and we hope that you have a great rest of your day take care.

This concludes the ever from Bio Sciences, Q1, 2020 financial results call you may now disconnect.

[music].

[music].

[music].

[music].